Faced with shrinking financial resources in a context of growing demand (chronic diseases, dependency, etc.), public authorities are increasingly focused on the efficiency of medicines and medical devices in health expenditure. This requires consideration of not only the individual medical dimension, but also collective dimensions.

In this context, the conditions for evaluation and access to market are a major concern for medicine and medical device companies.

OpenHealth real-life data is a key tool to objectivize this assessment and support decisions and recommendations. Its analysis provides real-world evidence of safety and efficacy required for the registration of new medicines and devices, evaluation of the risk/benefit ratio and the determination of price and reimbursement conditions.

Case study

Case study::Weight of the SelfCare Market

Case study Weight of the SelfCare Market

Extract of the results of the AFIPA barometer 2016                                          
July 2017

Download the presentation

Contact us

Nicolas GRELAUD - Commercial Director


Commercial Director


Our expertise

  • Medico-economic assessments
  • Market Access
  • Opportunity studies

The Hub - Health analytics at your finger tips
The first full web analytic tools for real-time health product tracking.Find out more